Quest for the right Drug

|

דוסטקסל סיקרוס 20 מ"ג/ מ"ל, תרכיז להכנת תמיסה לאינפוזיה DOCETAXEL SEACROSS 20 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION (DOCETAXEL ANHYDROUS, DOCETAXEL AS ANHYDROUS)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

תוך-ורידי : I.V

צורת מינון:

תרכיז להכנת תמיסה לאינפוזיה : CONCENTRATE FOR SOLUTION FOR INFUSION

Indications : התוויות

4.1 Therapeutic indications

Breast Cancer
• Docetaxel Seacross 20 mg/ml in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
• Docetaxel Seacross 20 mg/ml in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.
• Docetaxel Seacross 20 mg/ml monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.
• Docetaxel Seacross 20 mg/ml in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors over-express HER2 and who previously have not received chemotherapy for metastatic disease.
• Docetaxel Seacross 20 mg/ml in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.
• Doxorubicin and cyclophosphamide followed by Docetaxel Seacross 20 mg/ml in combination with trastuzumab (AC-TH) is indicated for the adjuvant treatment of patients with HER2 over- expressing, node-positive or high risk node-negative, breast cancer.
• Docetaxel Seacross 20 mg/ml in combination with trastuzumab, and carboplatin (TCH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk node- negative, breast cancer.
Non-small cell lung cancer: Docetaxel Seacross 20 mg/ml is indicated for the treatment of patients with advanced non-small cell lung carcinoma.

Ovarian cancer: Docetaxel Seacross 20 mg/ml is indicated for treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapy.

Prostate cancer: Docetaxel Seacross 20 mg/ml in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.

Esophageal cancer: Docetaxel Seacross 20 mg/ml for the treatment of esophageal cancer.

Gastric cancer: Docetaxel Seacross 20 mg/ml for the treatment of advanced gastric cancer.
Head and neck (SCCHN):
• Docetaxel Seacross 20 mg/ml as monotherapy in the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after failure of a previous chemotherapy regimen.
• Docetaxel Seacross 20 mg/ml in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

שימוש לפי פנקס קופ''ח כללית 1994 לא צוין
תאריך הכללה מקורי בסל לא צוין
הגבלות לא צוין

בעל רישום

A.L. MEDI-MARKET LTD.

רישום

170 41 36282 00

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

08.06.23 - עלון לרופא

עלון מידע לצרכן

לתרופה במאגר משרד הבריאות

דוסטקסל סיקרוס 20 מ"ג/ מ"ל, תרכיז להכנת תמיסה לאינפוזיה

קישורים נוספים

RxList WebMD Drugs.com